Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CTMX

CytomX Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for CTMX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 01:10 UTC.

What CytomX Therapeutics, Inc. does

CytomX is a clinical-stage biopharmaceutical company developing cancer therapies using its PROBODY technology platform, which masks biologics to activate selectively in tumors through protease-driven unmasking. The company's most advanced program is Varsetatug Masetecan (Varseta-M), a conditionally activated antibody-drug conjugate targeting EpCAM for colorectal cancer treatment, currently in Phase 1 clinical development.

Summarized from CytomX Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-17.54%

Revenue, margins & earnings

FY2021: net loss $116M on revenue $37M$37MFY2021FY2022: net loss $99M on revenue $53M$53MFY2022FY2023: net loss $569,000 on revenue $101M$101MFY2023FY2024 Revenue: $138M — margin split not shown (non-operating gains)$138MFY2024FY2025: net loss $17M on revenue $76M$76MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-16
  • 2026-10-16CEOStock Option (Right to Buy)Option exercise-101,793—
  • 2026-10-16CEOOption exercise101,793$161.9K
  • 2026-10-16CEOSale-101,793$461.9K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →
No qualifying company news in the archive. Full tape in the platform →

Questions this page answers

What does CytomX Therapeutics, Inc. do?

CytomX is a clinical-stage biopharmaceutical company developing cancer therapies using its PROBODY technology platform, which masks biologics to activate selectively in tumors through protease-driven unmasking.

When did CTMX last file with the SEC?

CytomX Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-22. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 01:10 UTC. This page is also available as JSON at /api/data?ticker=CTMX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CTMX and 5,000+ tickers.

Create a free account — keep CTMX
For your agent
GET /api/data?ticker=CTMX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt